Chengdu Olymvax Biopharmaceuticals Inc.SSE: 688319

(688319)"Chengdu Olymvax Biopharmaceuticals Inc."Report for Q3 2026

· Issued by Chengdu Olymvax Biopharmaceuticals Inc. via Shanghai Stock Exchange

Filed with SSE · Stock code 688319 · · 12 pages · Chinese

Summary by 6ix AI

The report indicates a decline in net profit attributable to shareholders compared to the previous year, alongside a decrease in total profit. The company also reported a significant drop in earnings per share and a reduction in research and development expenditures as a percentage of revenue. Total assets increased slightly, while total liabilities also rose, reflecting ongoing financial challenges.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Chengdu Olymvax Biopharmaceuticals Inc. on 6ix

Earlier from Chengdu Olymvax Biopharmaceuticals

Later from Chengdu Olymvax Biopharmaceuticals

All Chengdu Olymvax Biopharmaceuticals news releases